Items Tagged ‘trametinib’

July 21st, 2016

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

By

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Advanced melanoma refers to skin […]

View full entry

Tags: 2016, advanced, asco, BRAFV600E/K mutation, COMBI-d trial, dabrafenib, kinase inhibitors, mekinist, Melanoma, News, Stage IV Melanoma, Taflinar


October 8th, 2014

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma

By

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve melanoma. More than 8,000 people die of melanoma each […]

View full entry

Tags: Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, tafinalr, trametinib, zelboraf